10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know

PLEASANTON, Calif. , April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024.

10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024

Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution  PLEASANTON, Calif. , March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD Spatial Gene Expression product.

10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applications.

10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel

The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost PLEASANTON, Calif. , March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3.

10x Genomics Begins Commercial Shipments of Chromium GEM-X Products

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen announces the denial of 10x Genomics' petition for Inter Partes Review of the Vizgen-licensed patent asserted against 10x's Xenium Platform.

Vizgen Announces Denial of 10x Genomics' Petition for Inter Partes Review of Vizgen-Licensed Patent Currently Asserted Against 10x's Xenium Platform

Prime Medicine Inc

Recursion Pharmaceuticals

The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifetime.

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

PLEASANTON, Calif. , Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, at 2:50 p.m.

10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference

10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings

10x Genomics (TXG) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.15 per share a year ago.

10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates

Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif. , Feb. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided outlook for 2024.

10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024

10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

GEM-X, the next generation of the company's leading single cell technology architecture, enables higher performance at larger scale and lower cost Pre-orders now open for first two Chromium products powered by GEM-X; expected to ship in Q1 PLEASANTON, Calif. , Feb. 7, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of GEM-X, the next generation of the company's leading single cell technology.

10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology

New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology PLEASANTON, Calif. , Feb. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Florida.

10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations. Shareholders who have incurred losses on their investment in the Company are encouraged to contact the firm to learn about potentially recovering their losses. For more details on the investigation, visit: Click Here to Join the Investigation The investigation pertains to whether executives at the company misrepresented or f.

TXG Alert: Johnson Fistel Announces Investigation of 10x Genomics for Potential Securities Law Violations

PLEASANTON, Calif. , Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Thursday, February 15, 2024.

10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. The company celebrated the successful launch of its cutting-edge platform, Xenium, which offers exceptional vision and surpasses competitors in speed, sensitivity, and specificity. 10x Genomics is poised for sustained growth with its pursuit of scientific advancements, expanding applications in various fields, and strategic partnerships.

10x Genomics: Still Waiting For Entry

PLEASANTON, Calif. , Jan. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023.

10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results

PLEASANTON, Calif. , Dec. 21, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will present at the 42nd Annual J.P.

10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Founding Network Members Will Accelerate Access to Proof-of-Concept Data for Prospective Xenium Customers Worldwide PLEASANTON, Calif. , Dec. 20, 2023 /PRNewswire/ --  10x Genomics, Inc. , (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of its Xenium Catalyst Network, a global group of technically qualified research institutions that will accelerate access to Xenium proof-of-concept data for researchers worldwide.

10x Genomics Launches Xenium Catalyst Network

A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platforms PLEASANTON, Calif. , Dec. 19, 2023 /PRNewswire/ --  10x Genomics, Inc.  (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Nature Communications has published a 10x-conducted study using the Chromium Single Cell, Visium Spatial and Xenium In Situ platforms as part of an integrative approach to understand how tumor microenvironment differences influence invasiveness.

Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness

Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif. , Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently evaluated the technical performance of three spatial imaging platforms and found the Xenium In Situ platform demonstrated higher quality transcript counts per gene at higher specificity for 22 formalin-fixed paraffin-embedded (FFPE) tissues compared to NanoString's CosMx and Vizgen's MERSCOPE.

High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint

PLEASANTON, Calif. , Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the  NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.

News for 10X Genomics Stock (TXG)